Citations

Clear

6728 citation(s) found for "Li, Mark".

Acute Myeloid Leukemia Subtype‐Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy
Bolarinwa, Abiola , Al‐Kali, Aref , Mangaonkar, Abhishek A. , Saliba, Antoine N. , Hefazi, Mehrdad , Matin, A, Elliott, Michelle A. , Litzow, Mark R. , Hogan, William J. , Patnaik, Mrinal M. , Pardanani, Animesh , Foran, James M. , Punwani, Nathan , Palmer, Jeanne , Sproat, Lisa Z., Reichard, Kaaren K., He, Rong , Viswanatha, David S., Zepeda‐Mendoza, Cinthya , Gangat, Naseema , Begna, Kebede H. , Tefferi, Ayalew , Saliba, Antoine N. , Alkhateeb, Hassan B , Mangaonkar, Abhishek A. , Saliba, Antoine N , Hefazi, Mehrdad , Elliott, Michelle , Litzow, Mark R. , Hogan, William J , Shah, Mithun V , Patnaik, Mrinal , Pardanani, Animesh , Foran, James M , Badar, Talha , Murthy, Hemant S , Chen, Dong , He, Rong , Zepeda-Mendoza, Cinthya J , Gangat, Naseema , Tefferi, Ayalew , Saliba, Antoine N , Bolarinwa, Abiola B , Alkhateeb, Hassan B. , Shah, Meera , Badar, Talha , Murthy, Hemant S. , Chen, Dong , Reichard, Kaaren K.

Mayo Clinic

American Journal of Hematology | July 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajh.70443 | PMID 42470254 Get It

ABSTRACT We examined the prognostic value of routine NGS data in newly diagnosed acute myeloid leukemia (AML) treated with intensive (7 + 3 backbone) induction, specified by AML subtype. A contemporary (2015–2025) series of 545 Mayo Clinic patients (median age 56 years, females 44%) was considered. Median follow‐up was 49 months with 341 (63%) allogeneic hematopoietic stem cell transplantations (AHSCT) recorded. AML subtypes included core‐binding factor (CBF; N = 72; 13%), primary non‐CBF ( N = 403; 74%), post‐myelodysplastic syndromes (MDS) or post‐myelodysplastic/myeloproliferative neoplasms (post‐MDS‐MDS/MPN; N = 28; 5%), post‐MPN ( N = 15; 3%), and therapy‐related (t‐AML; N = 27; 5%). Corresponding complete remission rates, with/without count recovery (CR/CRi), were 89%, 76%, 64%, 27%, and 78% ( p < 0.01) and 5‐year transplant‐censored survival rates 68%, 57%, 21%, 0%, and 55% ( p < 0.01). In multivariable analyses, the prognostic value of specific mutations was mostly limited to primary non‐CBF AML where adverse karyotype (OR 1.9; p = 0.04) predicted inferior and FLT3 ‐ITD (OR 0.4; p < 0.01) or NPM1 MUT / FLT3 WT (OR 0.1; p < 0.01) superior CR/CRi while KRAS MUT (HR 8.8; p < 0.01), TP53 MUT (HR 5.4; p < 0.01), and TET2 MUT (HR 2.3; p = 0.01) predicted inferior and NPM1 MUT / FLT3 WT (HR 0.3; p = 0.01) superior survival. Prognostication in intensively‐treated AML should start with subtype specification and recognition of the limited value of NGS in non‐primary AML. Post‐MPN AML is particularly associated with dismal outcomes and should be prognostically distinguished from post‐MDS‐MDS/MPN AML. In primary non‐CBF AML, in addition to previously established risk factors, the favorable impact of FLT3 ‐ITD on achieving CR/CRi and the unfavorable impact of KRAS MUT and TET2 MUT on transplant‐censored survival were noted and require confirmation from additional studies.
Comparison of the Type, Impact, and Resolution of Complications Following Direct Anterior Versus Posterior Approach Total Hip Arthroplasty
Perez, Sergio F. Guarin , Roberts, Heather J. , Restrepo, Diego J. , Babalola, A O, Larson, Dirk R. , Ledford, Cameron K. , Bingham, Joshua S. , Trousdale, Robert T. , Taunton, Michael J. , Guarin Perez, Sergio F , Babalola, Abraham, Pagnano, Mark W , Trousdale, Robert T , Taunton, Michael J , Sierra, Rafael J , Restrepo, Diego J. , Larson, Dirk , Bingham, Joshua S , Ledford, Cameron K , Watts, Chad D. , Sierra, Rafael J.

Mayo Clinic

JBJS Open Access | July 17, 2026 | Volume: 11 | Issue: 3 | Pages: No page available

10.2106/jbjs.oa.26.00172 | PMID 42465617 Get It

Background: Prior studies have reported higher rates of periprosthetic fracture, superficial infection, and neurologic deficit with the direct anterior approach (DAA), and higher rates of dislocation with the posterior approach (PA) for total hip arthroplasty (THA). Despite these differences, the overall clinical burden of complications between approaches remains unclear. The purpose of this study was to compare the profiles, severity, impact, and resolution of 5 clinically important complications between DAA and PA THA. Methods: A retrospective review was conducted of 11,783 consecutive primary THAs performed between 2010 and 2021 across 3 centers within a single healthcare system, using either the DAA (n = 4,451) or the PA (n = 7,332). Complications assessed included dislocation, infection, periprosthetic fracture (PPFx), aseptic loosening, and neurologic deficit. Severity was graded using the Clavien-Dindo classification (I = minor, V = death). Impact was defined by reoperation burden, and outcomes were categorized as resolved or persistent. Kaplan-Meier survivorship and propensity-weighted Cox proportional hazards models were used to compare complication risk. Results: The overall 1-year risk of surgical complications did not differ between DAA and PA (hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.75-1.06; p = 0.208). Dislocation occurred more frequently with PA THA than DAA THA (1.9% vs. 0.4%; HR, 5.20; 95% CI, 3.04-8.90; p < 0.001). Superficial infections were more frequent with the DAA (1.6% vs. 0.8%; HR, 2.43; 95% CI, 1.68-3.53; p < 0.001). The risk of deep infection, PPFx, aseptic loosening, and neurologic deficit did not differ significantly between approaches. Among patients with complications, the proportion classified as severe (Clavien-Dindo III–V) was similar, and adjusted analyses showed no difference in the odds of severe complications (adjusted odds ratio 1.34 for PA vs DAA; 95% CI, 0.95-1.91; p = 0.099). Complication impact and resolution were likewise comparable. Conclusion: Although the profile of complications differed between DAA and PA THA, the severity, early clinical impact, and resolution of complications appeared similar. Notably, DAA was associated with a lower risk of dislocation and a higher risk of superficial infection compared with PA THA. Level of Evidence: Level III , Retrospective Comparative Study. See Instructions for Authors for a complete description of levels of evidence.
Liver parenchymal quality stratifies outcomes after hepatic resection for hepatocellular carcinoma
Hardy, Niall P. , Podrascanin, V. , Haque, Omar , Heard, Jessica, Z, Li , Dingfelder, Jule , Holst, Soeren, Lehner, Florian , Helmreich, Laura, Wukits, Iwan , Leiting, Jennifer L. , Warner, Susanne G, Smoot, Rory L., Kendrick, Michael L., Truty, M., Gyoeri, Georg, Gruenberger, Thomas, Taner, Timucin, Starlinger, Patrick P., Li, Zhihao , Ilmer, Matthias, Moeckli, Beat, Li, Zhihao , Santol, Jonas , Dong, Yawen , Pereyra, David , Heard, Jessica C. , Ilmer, Matthias , Moeckli, Beat , Warner, Susanne G. , Smoot, Rory L. , Kendrick, Michael L. , Truty, Mark J. , Heimbach, Julie K. , Györi, Georg, Gruenberger, Thomas , Starlinger, Patrick

Mayo Clinic

Liver Transplantation | July 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/lvt.0000000000000963 | PMID 42467975 Get It

Hepatic resection (HR) and liver transplantation (LT) are curative-intent treatments for hepatocellular carcinoma (HCC). Patients without cirrhosis are typically analyzed as a single group, obscuring potentially important differences between those with histologically normal liver and those with non-cirrhotic parenchymal disease. We aimed to characterize long-term outcomes following HR stratified by underlying parenchymal quality, with a contemporary LT cohort as an external benchmark. Retrospective cohort study of 662 adults undergoing curative-intent surgery for HCC at 2 tertiary centers (2010–2024). Resection patients (n=380) were stratified by non-tumor parenchymal histology into HR-Normal (n=84), HR-Diseased non-cirrhotic (n=159), and HR-Cirrhotic (n=137). A total of 282 LT recipients served as an external reference but were not entered into comparative models. Overall survival (OS) was analyzed by Kaplan–Meier and multivariable Cox regression, and recurrence by Fine–Gray competing-risks regression. Ninety-day mortality was low across resection strata (1.2%–3.2%). OS differed significantly across parenchymal groups (log-rank p =0.01), driven by superior outcomes in HR-Normal patients compared with both HR-Cirrhotic ( p =0.008) and HR-Diseased ( p =0.005). HR-Cirrhotic and HR-Diseased did not differ ( p =0.97). Five-year OS was 74.4%, 59.8% and 57.2%, respectively. On multivariable Cox regression, both cirrhosis (HR 2.03, 95% CI 1.16–3.54, p =0.01) and diseased non-cirrhotic parenchyma (HR 2.04, 95% CI 1.21–3.43, p =0.008) independently predicted death versus normal liver. Fine–Gray analysis confirmed higher recurrence risk in cirrhotic (sHR 2.09, p =0.01) and diseased non-cirrhotic (sHR 1.80, p =0.04) groups. The LT benchmark cohort achieved a 5-year OS of 82.4%. Histologically normal liver identifies a distinct HR subgroup with favorable oncologic outcomes. The conventional cirrhotic/non-cirrhotic dichotomy underestimates the prognostic impact of underlying parenchymal disease.
Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update
Nahleh, Zeina , Alfano, Catherine M. , Somerfield, Mark R. , Lee, Janie M. , Hieken, Tina J. , Magnuson, Allison , Rao, Ruta , Chew, Helen K., Chia, Stephen , Harvey, Brittany , Landsberger, Ellen , Mwanzi, Sitna , Parsons, Heather A. , Patt, DA , Sung, Hyuna , Rao, Ruta , Chia, Stephen K L , Harvey, Brittany E , Lim, Bora , Mwanzi, Sitna Ali , Parsons, Heather A , Sukumar, Jasmine S , Sung, Hyuna , Werutsky, Gustavo , Lustberg, Maryam , Hieken, Tina J , Alfano, Catherine M , Chew, Helen K. , Lim, Bora , Lustberg, Maryam B.

Mayo Clinic

Journal of Clinical Oncology | July 16, 2026 | Volume: 44 | Issue: 30 | Pages: 2953-2971

10.1200/jco-26-01700 | PMID 42462191 Get It

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the https://www.asco.org/practice-patients/guidelines/guideline-methodology . ASCO Guidelines follow the https://www.asco.org/about-asco/legal/conflict-interest-coi . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE To offer clinicians recommendations concerning breast cancer follow-up and surveillance after primary treatment. METHODS ASCO convened an Expert Panel to develop recommendations based on a systematic review and a formal consensus process. RESULTS One randomized controlled trial (RCT) was identified and formed the evidentiary basis for the surveillance mammography guideline recommendation. No RCTs were identified that evaluated different follow-up approaches by risk of relapse in patients treated for early-stage breast cancer. Given the dearth of evidence identified in the systematic review of the literature, formal modified Delphi consensus-based recommendations were generated. RECOMMENDATIONS The guideline offers recommendations on the role of a risk-based approach to the frequency and intensity of follow-up among patients with breast cancer in the adjuvant setting. Regular history, physical examination, and mammography are recommended for breast cancer follow-up. Either virtual or in-person visits can be offered. Certain patients at a high risk of cancer recurrence warrant closer surveillance, such as those patients with locally advanced disease or residual disease following neoadjuvant chemotherapy. Recommendations on the use of blood-based biomarkers and supplemental imaging are provided. Guideline recommendations will be updated once additional evidence-based tools become available to better individualize surveillance. Additional information is available at www.ascopubs.org/topics/asco-guidelines/breast-cancer .
Cross-cohort analysis of expression and splicing quantitative trait loci in TOPMed
Blackwell, Thomas W., Kachuri, Linda , Castaldi, Peter J. , Cho, Michael H. , Christenson, Stephanie A. , Durda, Peter , Gabriel, Stacey , Hersh, Craig P. , Huntsman, Scott , Hwang, S.-J., Joehanes, Roby, Johnson, Mari , Li, Xingnan , Lin, Honghuang , Liu, Ching‐Ti , Liu, Yongmei , Mak, Angel C. Y. , Manichaikul, Ani , Paik, David T. , Saferali, Aabida , Smith, Joshua D. , Taylor, Kent D. , Wang, Jiongming , Weinstock, Joshua S. , Weiss, Jeffrey, Wheeler, Heather E. , Zhou, Ying , Zoellner, Sebastian, Mestroni, Luisa , Graw, Sharon , Taylor, Matthew R.G. , Ortega, Victor E. , Johnson, Craig , Gan, Weiniu , Abecasis, Gonçalo , Nickerson, Deborah A. , Ardlie, Kristin G., Woodruff, Prescott G. , Bowler, Russell P. , Meyers, Deborah A. , Reiner, Alex, Kooperberg, Charles , Ziv, Elad , Vasan, Ramachandran S. , Silverman, Edwin K. , Rich, Stephen S., Heard‐Costa, Nancy L. , Tang, Hua, Rotter, Jerome I. , Smith, Albert V. , Aguet, François, Scott, Laura J. , Raffield, Laura M. , Parker, Stephen C.J. , Abe, Namiko, Almasy, Laura, Ament, Seth, Anugu, Pramod, Auer, Paul, Avramopoulos, Dimitrios, Balasubramanian, Adithya, Barr, R. Graham, Barwick, Lucas, Beaty, Terri, Becker, Diane, Becker, Lewis, Beitelshees, Amber, Benos, Takis, Bezerra, Marcos, Bis, Joshua, Brody, Jennifer, Broeckel, Ulrich, Broome, Jai, Bunting, Karen, Buth, Erin, Carey, Vincent, Carty, Cara, Casaburi, Richard, Chaffin, Mark, Chang, Christy, Chang, Yi-Cheng, Chavan, Sameer, Chen, Bo-Juen, Chen, Wei-Min, Choi, Seung Hoan, Chuang, Lee-Ming, Chung, Ren-Hua, Conomos, Matthew, Cornell, Elaine, Crandall, Carolyn, Crapo, James, Curtis, Jeffrey, Damcott, Coleen, David, Sean, Fuentes, Lisa de las, Vries, Paul de, Deka, Ranjan, DeMeo, Dawn, Devine, Scott, Dinh, Huyen, Doddapaneni, Harsha, Duan, Qing, Duggirala, Ravi, Eaton, Charles, Ekunwe, Lynette, Boueiz, Adel El, Emery, Leslie, Farber, Charles, Farek, Jesse, Franceschini, Nora, Frazar, Chris, Fu, Mao, Fullerton, Stephanie M., Fulton, Lucinda, Gao, Shanshan, Gao, Yan, Gass, Margery, Geiger, Heather, Ghosh, Auyon, Gignoux, Chris, Glahn, David, Gogarten, Stephanie, Gong, Da-Wei, Goring, Harald, Grine, Daniel, Gu, C. Charles, Guan, Yue, Hall, Michael, Han, Yi, Harris, Daniel, Heavner, Ben, Herrington, David, Hobbs, Brian, Hong, Elliott, Hoth, Karin, Hsiung, Chao (Agnes), Hu, Jianhong, Hung, Yi-Jen, Huston, Haley, Hwu, Chii Min, Jackson, Rebecca, Jain, Deepti, Johnsen, Jill, Johnston, Rich, Jones, Kimberly, Kessler, Michael, Khan, Alyna, Khan, Ziad, Kim, Wonji, Kimoff, John, Kinney, Greg, Kramer, Holly, Lange, Christoph, Lange, Ethan, Laurie, Cathy, Laurie, Cecelia, LeBoff, Meryl, Lee, Sandra, Lee, Wen-Jane, Levine, David, Lewis, Joshua, Li, Yun, Lin, Xihong, Liu, Simin, Liu, Yu, Make, Barry, Manning, Alisa, Manson, JoAnn, Martin, Lisa, Marton, Melissa, Mathai, Susan, May, Susanne, McArdle, Patrick, McDonald, Merry-Lynn, McFarland, Sean, McGoldrick, Daniel, McHugh, Caitlin, Mei, Hao, Meigs, James, Menon, Vipin, Min, Nancy, Moll, Matt, Momin, Zeineen, Montasser, May, Mychaleckyj, Josyf C, Naik, Rakhi, Naseri, Take, Natarajan, Pradeep, Nelson, Sarah C., Neltner, Bonnie, Nessner, Caitlin, Nkechinyere, Osuji, O'Connell, Jeff, O’Connor, Tim, Ochs-Balcom, Heather, Okwuonu, Geoffrey, Pankow, James, Parker, Cora, Peloso, Gina, Peralta, Juan Manuel, Perez, Marco, Perry, James, Peters, Ulrike, Phillips, Lawrence S, Pollin, Toni, Becker, Julia Powers, Boorgula, Meher Preethi, Psaty, Bruce, Qiao, Dandi, Rafaels, Nicholas, Rajendran, Mahitha, Rasmussen-Torvik, Laura, Ratan, Aakrosh, Reed, Robert, Regan, Elizabeth, Reupena, Muagututi‘a Sefuiva, Robillard, Rebecca, Roselli, Carolina, Ruczinski, Ingo, Runnels, Alexi, Russell, Pamela, Ryan, Kathleen, Sabino, Ester Cerdeira, Salimi, Shabnam, Salvi, Sejal, Salzberg, Steven, Sandow, Kevin, Santibanez, Jireh, Schwander, Karen, Sciurba, Frank, Sériès, Frédéric, Shetty, Amol, Shetty, Aniket, Silver, Brian, Skomro, Robert, Smith, Tanja, Smoller, Sylvia, Snively, Beverly, Stilp, Adrienne M., Storm, Garrett, Streeten, Elizabeth, Su, Jessica Lasky, Sung, Yun Ju, Sylvia, Jody, Szpiro, Adam, Taub, Margaret, Taylor, Simeon, Thornton, Timothy A., Threlkeld, Machiko, Tinker, Lesley, Tirschwell, David, Tiwari, Hemant, Tong, Catherine, Tsai, Michael, Vaidya, Dhananjay, Walker, Tarik, Wallace, Robert, Walts, Avram, Wang, Fei Fei, Wang, Heming, Watson, Karol, Watt, Jennifer, Weng, Lu-Chen, Wessel, Jennifer, Williams, Kayleen, Wilson, Carla, Wilson, James, Winterkorn, Lara, Wong, Quenna, Wu, Baojun, Xu, Huichun, Yanek, Lisa, Yang, Ivana, Zekavat, Seyedeh Maryam, Zhao, Snow Xueyan, Zhao, Wei, Zhu, Xiaofeng, Rich, Stephen S. , Pankow, James S. , Reiner, Alex P. , Aguet, François , Johnson, W. Craig , Ardlie, Kristin , Orchard, Peter , Kachuri, Linda , Castaldi, Peter J , Cho, Michael H , Christenson, Stephanie A , Durda, Peter , Hersh, Craig P , Huntsman, Scott , Hwang, Seungyong , Joehanes, Roby , Johnson, Mari , Li, Xingnan , Lin, Honghuang , Liu, Ching-Ti , Liu, Yongmei , Mak, Angel C Y , Manichaikul, Ani W , Paik, David T , Smith, Joshua D , Taylor, Kent D , Tracy, Russell P , Wang, Jiongming , Wang, Mingqiang , Weinstock, Joshua S , Weiss, Jeffrey , Wheeler, Heather E , Zhou, Ying , Zöllner, Sebastian , Wu, Joseph C , Mestroni, Luisa , Graw, Sharon , Taylor, Matthew R G , Ortega, Victor E , Johnson, W Craig , Gan, Weiniu , Gupta, Namrata , Ardlie, Kristin , Woodruff, Prescott G , Bowler, Russell P , Reiner, Alexander P , Kooperberg, Charles , Ziv, Elad , Vasan, Ramachandran S , Silverman, Edwin K , Rich, Stephen S , Heard-Costa, Nancy , Tang, Hua , Rotter, Jerome I , Smith, Albert V , Levy, Daniel , Aguet, François , Scott, Laura J , Raffield, Laura M , Parker, Stephen C J , Pankow, James S , Tracy, Russell P. , Wu, Joseph C. , Larson, Martin G. , Cupples, L. Adrienne , Abe, Namiko, Almasy, Laura, Ament, Seth, Anugu, Pramod, Auer, Paul, Avramopoulos, Dimitrios, Balasubramanian, Adithya, Barr, R. Graham, Barwick, Lucas, Beaty, Terri, Becker, Diane, Becker, Lewis, Beitelshees, Amber, Benos, Takis, Bezerra, Marcos, Bis, Joshua, Brody, Jennifer, Broeckel, Ulrich, Broome, Jai, Bunting, Karen, Buth, Erin, Carey, Vincent, Carty, Cara, Casaburi, Richard, Chaffin, Mark, Chang, Christy, Chang, Yi-Cheng, Chavan, Sameer, Chen, Bo-Juen, Chen, Wei-Min, Choi, Seung Hoan , Chuang, Lee-Ming, Chung, Ren-Hua, Conomos, Matthew, Cornell, Elaine, Crandall, Carolyn, Crapo, James, Curtis, Jeffrey, Damcott, Coleen, David, Sean, Fuentes, Lisa de las, Vries, Paul de, Deka, Ranjan, DeMeo, Dawn, Devine, Scott, Dinh, Huyen, Doddapaneni, Harsha, Duan, Qing, Duggirala, Ravi, Eaton, Charles, Ekunwe, Lynette, Boueiz, Adel El, Emery, Leslie, Farber, Charles, Farek, Jesse, Franceschini, Nora, Frazar, Chris, Fu, Mao, Fullerton, Stephanie M., Fulton, Lucinda, Gao, Shanshan, Gao, Yan, Gass, Margery, Geiger, Heather, Ghosh, Auyon, Gignoux, Chris, Glahn, David, Gogarten, Stephanie, Gong, Da-Wei, Goring, Harald, Grine, Daniel, Gu, C. Charles, Guan, Yue, Hall, Michael, Han, Yi, Harris, Daniel, Heavner, Ben, Herrington, David, Hobbs, Brian, Hong, Elliott, Hoth, Karin, Hsiung, Chao (Agnes), Hu, Jianhong, Hung, Yi-Jen, Huston, Haley, Hwu, Chii Min, Jackson, Rebecca, Jain, Deepti, Johnsen, Jill, Johnston, Rich, Jones, Kimberly, Kessler, Michael, Khan, Alyna, Khan, Ziad, Kim, Wonji, Kimoff, John, Kinney, Greg, Kramer, Holly, Lange, Christoph, Lange, Ethan, Laurie, Cathy, Laurie, Cecelia, LeBoff, Meryl, Lee, Sandra, Lee, Wen-Jane, Levine, David, Lewis, Joshua, Li, Yun, Lin, Xihong, Liu, Simin, Liu, Yu, Make, Barry, Manning, Alisa, Manson, JoAnn, Martin, Lisa, Marton, Melissa, Mathai, Susan, May, Susanne, McArdle, Patrick, McDonald, Merry-Lynn, McFarland, Sean, McGoldrick, Daniel, McHugh, Caitlin, Mei, Hao, Meigs, James, Menon, Vipin, Min, Nancy, Moll, Matt, Momin, Zeineen, Montasser, May, Mychaleckyj, Josyf C, Naik, Rakhi, Naseri, Take, Natarajan, Pradeep, Nelson, Sarah C., Neltner, Bonnie, Nessner, Caitlin, Nkechinyere, Osuji, O'Connell, Jeff, O’Connor, Tim, Ochs-Balcom, Heather, Okwuonu, Geoffrey, Parker, Cora, Peloso, Gina, Peralta, Juan Manuel, Perez, Marco, Perry, James, Peters, Ulrike, Phillips, Lawrence S, Pollin, Toni, Becker, Julia Powers, Boorgula, Meher Preethi, Psaty, Bruce, Qiao, Dandi, Rafaels, Nicholas, Rajendran, Mahitha, Rasmussen-Torvik, Laura, Ratan, Aakrosh, Reed, Robert, Regan, Elizabeth, Reupena, Muagututi‘a Sefuiva, Robillard, Rebecca, Roselli, Carolina, Ruczinski, Ingo, Runnels, Alexi, Russell, Pamela, Ryan, Kathleen, Sabino, Ester Cerdeira, Salimi, Shabnam, Salvi, Sejal, Salzberg, Steven, Sandow, Kevin, Santibanez, Jireh, Schwander, Karen, Sciurba, Frank, Sériès, Frédéric , Shetty, Amol, Shetty, Aniket, Silver, Brian, Skomro, Robert, Smith, Tanja, Smoller, Sylvia, Snively, Beverly, Stilp, Adrienne M., Storm, Garrett, Streeten, Elizabeth, Su, Jessica Lasky, Sung, Yun Ju, Sylvia, Jody, Szpiro, Adam, Taub, Margaret, Taylor, Simeon, Thornton, Timothy A., Threlkeld, Machiko, Tinker, Lesley, Tirschwell, David, Tiwari, Hemant, Tong, Catherine, Tsai, Michael, Vaidya, Dhananjay, Walker, Tarik, Wallace, Robert, Walts, Avram, Wang, Fei Fei, Wang, Heming, Watson, Karol, Watt, Jennifer, Weng, Lu-Chen, Wessel, Jennifer, Williams, Kayleen, Wilson, Carla, Wilson, James, Winterkorn, Lara, Wong, Quenna, Wu, Baojun, Xu, Huichun, Yanek, Lisa, Yang, Ivana, Zekavat, Seyedeh Maryam, Zhao, Snow Xueyan, Zhao, Wei, Zhu, Xiaofeng

Mayo Clinic

Science | July 16, 2026 | Volume: 393 | Issue: 6808 | Pages: No page available

10.1126/science.adx2989 | PMID 42462027 Get It

Most genetic variants associated with complex traits are hypothesized to regulate gene expression. To understand the genetics underlying gene expression variability, we characterized 14,324 RNA-sequencing samples from the Trans-Omics for Precision Medicine program and performed expression and splicing quantitative trait locus (e/sQTL) analyses in six tissues and cell types, including whole blood ( n = 6454) and lung ( n = 1291). We detected tens of thousands of secondary cis-e/sQTLs, showing that secondary cis-e/sQTL discovery remains unsaturated. We fine-mapped UK Biobank–derived genome-wide association study (GWAS) signals from 164 traits and identified e/sQTL colocalizations for 10,611 GWAS signals, including 7096 that colocalize with secondary e/sQTLs. Our results suggest that even larger e/sQTL analyses will uncover additional secondary e/sQTLs, further benefiting GWAS interpretation.
Spatial Configuration of Pancreatic Cancer Is Associated with Disease Recurrence after Neoadjuvant Therapy and Curative-Intent Resection
Cisneros, Luis , Toruner, Merih Deniz , Siddiqui, Zafar , Maraone, Andrea V. , Lin, Miranda , Xiao, Alexander , Thiels, Cornelius A. , Truty, Mark J. , George, Ben , Jazieh, Khalid , Scheel, Robert , Hartley, Christopher , Elhalaby, Rofyda , Dizona, Paul , Fernández-Zapico, Martín E. , Carr, Ryan M. , Cisneros, Luis H , Toruner, Merih D , Xiao, Alexander H , Thiels, Cornelius A , Scheel, Robb , McWilliams, Robert R , Maley, Carlo C. , Hartley, Christopher P , Elhalaby, Rofyda Essam , Dizona, Paul , Shi, Qian , Fernandez-Zapico, Martin E , Carr, Ryan M , Truty, Mark J , Garzaro, Andrea V. Maraone , Lin, Miranda , George, Ben , McWilliams, Robert R. , Shi, Qian

Mayo Clinic

Clinical Cancer Research | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF16

10.1158/1078-0432.ccr-25-4968 | PMID 42456051 Get It

Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) frequently recurs after neoadjuvant therapy (NT) and curative-intent resection. Although major pathologic response predicts favorable outcomes, most patients achieve only minor response with a heterogeneous recurrence risk. We asked whether the spatial organization of residual PDAC encodes clinically relevant biology beyond residual tumor burden. Experimental Design: In a retrospective cohort of 203 patients with resected PDAC treated with NT and restricted to minor pathologic response, routine hematoxylin and eosin (H&E) whole-slide images were segmented into cancer and stroma using an artificial intelligence–enabled pipeline. Spatial composition (patch density, edge density) and configuration (compactness/complexity, intermixing) were quantified and tested for associations with disease-free survival (DFS) using multivariable models adjusted for standard clinicopathologic factors. Results: Shorter DFS was associated with a fragmented, interface-rich tumor–stroma ecology featuring higher edge density and diversity and reduced homotypic aggregation, independent of clinicopathologic variables. Two spatial risk models were independently prognostic: (i) cancer mean shape index plus stromal shape index variability [adjusted hazard ratio (HR), 1.71; P = 0.003] and (ii) mean stromal patch area plus edge density (adjusted HR, 2.19; P = 0.002). Both models stratified outcomes in which pathologic response grading and residual cancer area did not. High-risk configurations were further associated with reduced intratumoral tumor-infiltrating lymphocyte (TIL) density and infiltration ratio, with relative TIL accumulation at the cancer periphery and within the stroma, consistent with an immune-excluded phenotype. Conclusions: Residual cancer–stroma topology quantified from standard H&E slides yields independent prognostic signals after NT in PDAC, provides a cellular immune correlate for spatial risk, and motivates prospective validation and spatially informed adjuvant strategies.
Development and Validation of a Simplified Martin-Hopkins LDL-C Equation Using Machine Learning
Park, Jihwan, Fan, Leon, Marzinke, Mark A., Sokoll, Lori J., Muthukumar, Alagarraju, Murphy, Sabina A., Sabatine, Marc S., Gurudu, Rachana, Meeusen, Jeff W., Martin, Seth S., Marzinke, Mark A. , Sokoll, Lori J. , Muthukumar, Alagarraju , Murphy, Sabina A. , Sabatine, Marc S. , Gurudu, Rachana, Meeusen, Jeffrey W. , Martin, Seth S.

Mayo Clinic

JAMA Cardiology | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamacardio.2026.2314 | PMID 42455545 Get It

Importance Although the Martin-Hopkins equation is widely validated and used to estimate low-density lipoprotein cholesterol (LDL-C) for clinical care, a simplified equation could streamline implementation and enable broader adoption. Objective To develop a simplified machine learning–based alternative to the Martin-Hopkins equation using multivariate adaptive regression splines (LDL-C–MH-MARS) and compare its performance with the Friedewald (LDL-C–F), Sampson–National Institutes of Health (LDL-C–S), Modified Sampson (LDL-C–MS), and Martin-Hopkins (LDL-C–MH) equations. Design, Setting, and Participants The Very Large Database of Lipids is a cross-sectional database of clinical lipid measurements from a population-representative convenience sample of adult and pediatric patients. Lipid measurements were performed by Vertical Auto Profile ultracentrifugation between October 1, 2015, and June 30, 2019. The study included patients with complete lipid panel data who were randomly assigned to a training set and a test set. External validation against preparative ultracentrifugation-based LDL-C measurements was performed in reference laboratory datasets from the Mayo Clinic (broad LDL-C concentrations) and the Further Cardiovascular Outcomes Research With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Subjects with Elevated Risk (FOURIER) trial (observations from patients with low LDL-C concentrations while taking evolocumab). Study data were analyzed from January to October 2025. Exposures LDL-C–F, LDL-C–S, LDL-C–MS, LDL-C–MH, and LDL-C–MH-MARS equations. Main Outcomes and Measures Accuracy of estimated vs ultracentrifugation-measured LDL-C concentration based on bias, root mean square error (RMSE), and concordance by guideline-based categories. Results The study included 4 939 528 patients (mean [SD] age, 56 [16] years; 2 635 486 female [53%]) with complete lipid panel data who were randomly assigned to a training set (n = 3 292 889) and a test set (n = 1 646 639). LDL-C–MH-MARS equation demonstrated a very low median (IQR) bias of −0.1 (−2.1 to 1.8) mg/dL (to convert to millimoles per liter, multiply by 0.0259), comparable with LDL-C–MH. The median (IQR) difference between the MARS and original Martin-Hopkins equations (ie, LDL-C–MH-MARS – LDL-C–MH) was −0.5 (−1.2 to 0) mg/dL, further suggesting comparability between the 2 methods. The RMSE was smallest for LDL-C–MH-MARS (4.7 mg/dL) and LDL-C–MH (4.9 mg/dL), followed by LDL-C–S (5.8 mg/dL), LDL-C-MS (6.0 mg/dL), and LDL-C–F (7.2 mg/dL). The proportion of patients correctly classified according to clinical categories was nearly identical for LDL-C–MH-MARS (89.7%) and LDL-C–MH (89.6%) but lower for LDL-C–S (86.3%), LDL-C–MS (84.7%), and LDL-C–F (83.1%). The LDL-C–MH-MARS, LDL-C–MH, LDL-C–MS, LDL-C–S, and LDL-C–F equations underestimated LDL-C concentration in 16%, 17%, 28%, 39%, and 60%, respectively, when classifying LDL-C less than 70 mg/dL in patients with triglyceride concentrations of 200 to 399 mg/dL (to convert to millimoles per liter, multiply by 0.0113). The patterns of results were similar in external validation datasets, with the LDL-C–MH-MARS and LDL-C–MH equations demonstrating the highest accuracy. Conclusions and Relevance Study results suggest that the new machine learning–based LDL-C equation provided results comparable with those of the original Martin-Hopkins method while simplifying implementation to a single equation.
Consensus on biomarker utility for ACTH-dependent Cushing syndrome: a Pituitary Society Modified Delphi Panel
Fleseriu, Maria , Biller, Beverly M. K. , Reincke, Martín , Мелмед, Шломо , Group, the Pituitary Society International Cushing Syndrome Delphi Panel Consensus, Akirov, Amit , Araki, Takako, Auchus, Richard, Ben-Shlomo, Anat , Bertherat, Jérôme, Biermasz, Nienke R, Castinetti, Frédéric, Ceccato, Filippo, Christ-Crain, Mirjam, Feelders, Richard A. , Findling, James W. , Gadelha, Monica, Geer, Eliza B, Giustina, Andrea, Grossman, Ashley, Gurnell, Mark, Hanzu, Felicia, Hinojosa-Amaya, Jose M, Isand, Kristina , Isidori, Andrea M, Kadioğlu, Pinar, Karavitaki, Niki, McCormack, A I, Nieman, Lynnette, Nowak, Elisabeth, Pivonello, Rosario, Salvatori, Roberto , Stewart, Paul M., Tabarin, Antoine, Takahashi, Yutaka, Theodoropoulou, Marily , Valassi, Elena, Varlamov, Elena V , Walia, Rama, Wass, John, Cheung, Cassandra, Priven, Mariel , Brown, Marielle, Biller, Beverly M K , Bancos, Irina , Fukuoka, Hidenori , Reincke, Martin , Newell-Price, John , Melmed, Shlomo , Bancos, Irina , Newell‐Price, John , Bertherat, Jérôme , Bidlingmaier, Martin , Biermasz, Nienke Ruurdje , Castinetti, Frédéric , Ceccato, Filippo , Christ‐Crain, Mirjam , Gadelha, Mônica R. , Geer, Eliza B. , Glezer, Andréa , Giustina, Andrea , Greenman, Yona , Grossman, Ashley, Gurnell, Mark , Hanzu, Felicia Alexandra , Hinojosa‐Amaya, José Miguel , Isidori, Andrea M. , Kadıoğlu, Pınar , Karavitaki, Niki , Langlois, Fabienne , Nieman, Lynnette K. , Nowak, Elisabeth , Pereira, Alberto M. , Petersenn, Stephan , Pivonello, Rosario , Tabarin, Antoine , Valassi, Elena , Vila, Greisa , Brown, Marielle, Fleseriu, Maria

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1210/clinem/dgag279 | PMID 42460773 Get It

Abstract Context Biochemical test results are central to clinical decision-making for the diagnosis and management of Cushing syndrome (CS). With emerging research and increasing availability of different tests, updated consensus on the utility of these biomarkers is warranted. Objective To establish an updated consensus on the role of biomarkers in the diagnosis and monitoring of adrenocorticotropic hormone-dependent CS, address novel therapeutic approaches, and identify areas for future research. Design A modified 2-round Delphi panel was conducted. Consensus was defined as ≥70% agreement/disagreement for Likert-scale statements or ≥70% selection of the same option for single-choice questions. Setting Participants represented a range of international expertise. Participants Forty-one participants took part in the Delphi panel, with no attrition between rounds (one nonclinician was not required to complete the second round). An 8-member Steering Committee guided statement development. Results Of statements designed to reach consensus, 45% (14/31) and 44% (11/25) statements reached consensus in Rounds 1 and 2, respectively. Notably, most panelists reported the use of late-night salivary cortisol for diagnosis of mild CS and for monitoring following pituitary surgery or medical or radiation therapy. Most panelists responded that block-and-replace therapies can be considered in patients with cyclical or severe CS, and consensus was reached that restoration of circadian rhythm is a treatment goal for patients with CS. Conclusion Areas of alignment among experts on the diagnosis and monitoring of CS are presented. The findings from this study are intended to support clinicians in their clinical decision-making and highlight priority areas for future research.
Minor stroke, major stakes: impact of procedure duration on thrombectomy outcomes in minor stroke
Kasem, Rahim Abo, Baba, Bachar El, Ma, Tianwen, Zelmanovich, Rebecca, Pabaney, Aqueel, Khelo, Roy Raheb, Giraudo, Francesca, Chandler, Katherine, Elawady, Sameh Samir, Chalhoub, Reda, Levitt, Michael R., Mascitelli, Justin, Cawley, Charles Michael, Akbik, Feras, Chisango, Zvipo, Wolfe, Stacey Quintero, Kim, Joon-Tae, Jabbour, Pascal, Yoshimura, Shinichi, Maier, Ilko, Ogilvy, Christopher S., Ezzeldin, Mohamad, Psychogios, Marios-Nikos, Siddiqui, Fazeel, Navia, Pedro, Goyal, Nitin, Arthur, Adam S., Romano, Daniele G., Fragata, Isabel, Daglioglu, Ergun, Altschul, David, Park, Min S., Crosa, Roberto, Brinjikji, Waleed, Moss, Mark, Dye, Justin, Alaraj, Ali, Kan, Peter, Limaye, Kaustubh, Mokin, Maxim, Starke, Robert M., Spiotta, Alejandro M., Grossberg, Jonathan A , Alawieh, Ali M., Kasem, Rahim Abo , Baba, Bachar El , Ma, Tianwen , Zelmanovich, Rebecca , Pabaney, Aqueel, Khelo, Roy Raheb , Giraudo, Francesca, Chacón-Aponte, Ariana Alejandra , Chandler, Katherine , Elawady, Sameh Samir , Howard, Brian M , Levitt, Michael R. , Grandhi, Ramesh , Mascitelli, Justin R , Cawley, Charles Michael, Akbik, Feras , Chisango, Zvipo Mutsa , Wolfe, Stacey Q , Kim, Joon‐Tae , Jabbour, Pascal , Maier, Ilko , Ogilvy, Christopher S. , Ezzeldin, Mohamad , Psychogios, Marios‐Nikos , Navía, Pedro , Goyal, Nitin , Arthur, Adam S., Romano, Daniele Giuseppe , Fragata, Isabel , Dağlıoğlu, Ergün , Altschul, David , Crosa, Roberto , Brinjikji, Waleed , Moss, Mark, Dye, Justin , Alaraj, Ali , Limaye, Kaustubh , Mokin, Maxim , Starke, Robert M. , Spiotta, Alejandro M , Alawieh, Ali

Mayo Clinic

Journal of Neurosurgery | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-12

10.3171/2026.2.jns252558 | PMID 42468039 Get It

OBJECTIVE Endovascular thrombectomy (EVT) for acute large-vessel occlusion stroke is well established, yet its role in patients presenting with minor stroke symptoms (National Institutes of Health Stroke Scale [NIHSS] score < 6) remains unclear. Prior studies have not accounted for intraprocedural factors that may influence outcomes in this subgroup. METHODS The authors analyzed 5693 patients from the STAR (Stroke and Thrombectomy and Aneurysm Registry), including 398 with low NIHSS scores, to evaluate the association between procedure time (PT) and outcomes. Among patients with low NIHSS scores, propensity score matching was used to compare outcomes between those with PT ≤ 35 versus > 35 minutes, a cutoff defined using receiver operating characteristic curve analysis. The authors performed a meta-analysis of studies reporting best medical management (BMM) outcomes in patients with low NIHSS scores. To compare these with EVT-treated patients, a matched BMM comparator cohort using stratification on pooled baseline characteristics was constructed. Outcomes included 90-day functional independence (modified Rankin Scale [mRS] scores 0–2), intracranial hemorrhage, and mortality. RESULTS PT had a stronger negative effect on outcomes in patients with low NIHSS scores compared with those with high scores, with a steeper decline in functional independence per minute of PT (slope: –0.45% vs –0.21%; p = 0.03 for interaction). Among patients with low scores, PT ≤ 35 minutes was associated with higher 90-day functional independence compared with the propensity score–matching cohort with PT > 35 minutes (82.6% vs 59.0%, p < 0.001). When benchmarked against BMM (75.2% mRS scores 0–2), patients undergoing EVT within 35 minutes had superior outcomes (85.1%, p = 0.047). In contrast, EVT with PT > 35 minutes resulted in worse outcomes than BMM (mRS scores 0–2: 59.8%, p = 0.008). The number needed to treat for PT ≤ 35 minutes was 10, whereas PT > 35 minutes yielded a number needed to harm of 6. CONCLUSIONS PT critically modulates the benefit of EVT in minor stroke. While efficient EVT yields better outcomes than BMM, prolonged procedures are associated with harm. These findings may explain prior inconsistent evidence on EVT in patients with low NIHSS scores and underscore the need to individualize procedural thresholds in this population.
Digital biomarkers in cardiovascular medicine: a scientific statement of the ESC Working Group on e-Cardiology, the ESC Working Group on Cardiovascular Pharmacotherapy, the European Heart Rhythm Association (EHRA) of the ESC, the Association for Acute Card
Corredoira, Pablo Manuel Fernández, Kaski, Juan Carlos, Duncker, David , Tubaro, Marco , Schuuring, Mark J. , Mamas, Mamas, Petersen, Steffen E, Kemps, Hareld M C, Locati, Emanuela T, Hill, Loreena, Keser, Nurgül , Verstrael, Axel , Friedman, P A, Casado-Arroyo, Rubén , Corredoira, Pablo M , Dörr, Marcus , Wilhelm, Matthias , Schuuring, Mark J , Mueller, Christian , Dilaveris, Polychronis E , Casado-Arroyo, Rubén , Duncker, David , Kaski, Juan Carlos , Wilhelm, Matthias , Petersen, Steffen E. , Vidal-Pérez, Rafael , Jensen, Magnus Thorsten , LUCIA, RAFFAELE DE , Hill, Loreena , Ramírez, Julia , Cluitmans, Matthijs J M , Friedman, Paul A.

Mayo Clinic

European Heart Journal - Digital Health | July 14, 2026 | Volume: 7 | Issue: 6 | Pages: No page available

10.1093/ehjdh/ztag074 | PMID 42491935 Get It

Abstract Cardiovascular disease is the leading cause of morbidity and mortality globally, imposing a substantial patient burden. Digital biomarkers derived from digital health technologies enable quantifiable, near-continuous, real-world capture of pathophysiological signals and are increasingly used across cardiovascular medicine. Their growth is often supported by big data analytics, artificial intelligence and connected sensors within the Internet of Things. This scientific statement systematically reviews digital biomarkers, their clinical utility across the cardiovascular care continuum, and summarizes major methodological and implementation challenges. We searched PubMed/MEDLINE, Embase and Scopus for phase III–IV cardiovascular trials published between 1 January 2019 and 1 August 2024 that collected digital biomarkers. We identified 541 records and included 32 trials (40 reports) enrolling 32 246 participants (44.71% women; mean age 66.2 ± 11.0 years). Heart failure was the most frequent target condition (16 trials, 50%), followed by cardiac implantable electronic devices trials (12 trials, 38%). Digital biomarkers included cardiac rhythm and heart rate, blood pressure, body weight, impedance-based measures, haemodynamic pressures, and physical activity and sleep patterns captured using diverse sensor technologies. Methodological quality was good (modal quality score 5; range 3–7), although most trials were unblinded. Current studies suggest potential clinical utility in selected cardiovascular conditions. Implementation remains challenging because of measurement variability, privacy and regulatory requirements, affordability and reimbursement barriers and inequities in access. Robust validation and outcome- and cost-effectiveness evidence are still needed. Registration number: CRD42024573879.